Antibody response to a seven-valent pneumococcal conjugated vaccine in patients with ataxia-telangiectasia.
Immunodeficiency is a characteristic feature of ataxia-telangiectasia (A-T). Humoral immunodeficiency generally consists of hypogammaglobulinemia and impaired antibody response to bacterial and viral antigens. We previously observed defective antibody response to 23-valent pneumococcal polysaccharide vaccine (PPV) in 96% of 29 patients with A-T. In this study, we investigated the antibody response to a seven-valent pneumococcal conjugate vaccine, PCV7, in 14 patients with A-T. IgG antibody levels to four pneumococcal serotypes, 6B, 14, 19F, 23F, which were included in PCV7, were measured by ELISA in pre- and postimmunization serum samples. Antibody titers against each individual Streptococcus pneumoniae serotype was considered to be positive when serotype specific pneumococcal antibody titer was higher than 10% (>10 U/mL) of the reference plasma pool level. However, when the fold increase (FI) in postimmunization antibody titer was less than two, the subject was determined to be unresponsive to the given serotype. The values were compared with the results obtained in age- and ethnic-matched children after one dose of PPV. Only two patients produced antibodies to one serotype each; one to serotype 19 with a fold increase of <2, and the other to serotype 23F with a fold increase of 5.7 based on the above criteria, although the differences between pre- and postvaccine antibody titers for serotypes 14, 19, and 23 appeared to be statistically significant. In conclusion, A-T patients failed to respond to one dose of PCV7 vaccine. Two or more doses of conjugated vaccine may be required to recruit the help of T lymphocytes in A-T patients.
Sanal
Ozden
O
Immunology Division, Ihsan Dogramaci Children's Hospital, Hacettepe University, 06100 Ankara, Turkey. sanaloz@tr.net
Ersoy
Fugen
F
Tezcan
Ilhan
I
Metin
Ayse
A
Turul
Tuba
T
Gariboglu
Semra
S
Yel
Leman
L
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D001260:Ataxia Telangiectasia / Q000276:immunology / Q000628:therapy*; D016022:Case-Control Studies; D002648:Child; D006801:Humans; D022242:Pneumococcal Vaccines / Q000276:immunology / Q000627:therapeutic use*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000276:immunology; D017211:Treatment Failure
D022242:Pneumococcal Vaccines